328 related articles for article (PubMed ID: 33910041)
1. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.
Alexander M; Culos K; Roddy J; Shaw JR; Bachmeier C; Shigle TL; Mahmoudjafari Z
Transplant Cell Ther; 2021 Jul; 27(7):558-570. PubMed ID: 33910041
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Oluwole OO; Dholaria B; Knight TE; Jain T; Locke FL; Ramsdell L; Nikiforow S; Hashmi H; Mooney K; Bhaskar ST; Morris K; Gatwood K; Baer B; Anderson LD; Hamadani M
Transplant Cell Ther; 2024 Feb; 30(2):131-142. PubMed ID: 37951502
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Strati P; Gregory T; Majhail NS; Jain N
JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
Sharma A; Singh V; Deol A
Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
6. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
[TBL] [Abstract][Full Text] [Related]
7. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
8. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM; Pennings ERA; Kos M; Mutsaers PGNJ; Lugtenburg PJ; van Meerten T; van Doesum JA; Minnema MC; Jak M; van Dorp S; Vermaat JSP; van der Poel MWM; van Oijen MGH; Kuipers MT; Nijhof IS; Kersten MJ
JCO Oncol Pract; 2023 Mar; 19(3):e407-e416. PubMed ID: 36508702
[TBL] [Abstract][Full Text] [Related]
9. Toxicities associated with adoptive cellular therapies.
Hansen DK; Dam M; Faramand RG
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
[TBL] [Abstract][Full Text] [Related]
10. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
Dabas P; Danda A
Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
[TBL] [Abstract][Full Text] [Related]
11. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
Ahmed N; Shahzad M; Shippey E; Bansal R; Mushtaq MU; Mahmoudjafari Z; Faisal MS; Hoffmann M; Abdallah AO; Divine C; Hamadani M; McGuirk J; Shune L
Transplant Cell Ther; 2022 Jul; 28(7):358-364. PubMed ID: 35429662
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T-cell therapy: Prospective observational study of unplanned emergency department presentations.
Bak GG; Micklethwaite K; Maddock K; Coggins A
Emerg Med Australas; 2023 Dec; 35(6):1034-1037. PubMed ID: 37669879
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Chodnicki KD; Prasad S
Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
Gauthier J; Turtle CJ
Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
[TBL] [Abstract][Full Text] [Related]
17. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
18. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
19. Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.
Gatwood K; Mahmoudjafari Z; Baer B; Pak S; Lee B; Kim H; Abernathy K; Dholaria B; Oluwole O
Clin Hematol Int; 2024; 6(2):11-20. PubMed ID: 38817307
[TBL] [Abstract][Full Text] [Related]
20. Secretory co-factors in next-generation cellular therapies for cancer.
Okuma A; Ishida Y; Kawara T; Hisada S; Araki S
Front Immunol; 2022; 13():907022. PubMed ID: 36059449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
